Rituximab + Lenalidomide (R²/AUGMENT)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-RITUXIMAB DRUG-LENALIDOMIDE |
|---|
| ID | REG-RITUXIMAB-LENALIDOMIDE-R2 |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-05-09 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-AUGMENT-LEONARD-2019 SRC-NCCN-BCELL-2025 |
Notes
AUGMENT R² schedule: rituximab 375 mg/m² IV day 1 + lenalidomide 20 mg PO days 1-21 q28d × 12 cycles. Chemo-free. PFS HR 0.46 (Leonard 2019). REMS program for lenalidomide (RevAssist/Revlimid-REMS in US; equivalent pregnancy-prevention program in UA) — mandatory dual-contraception, monthly pregnancy tests. VTE prophylaxis required (aspirin 81-325 mg QD minimum; LMWH for high-risk patients). HBV screening mandatory pre-rituximab. Grade 3-4 neutropenia 50% — monitor CBC monthly; G-CSF support as needed.
Used By
Indication
IND-FL-2L-R2- IND-FL-2L-R2